ArticleNature communications2021

Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.

Marcel A Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.